Gefitinib是一种有效的表皮生长因子受体(EGFR)抑制剂，其在NR6wtEGFR细胞中的 IC₅₀ 值为2-37 nM。Gefitinib与EGFR的ATP结合，抑制EGFR酪氨酸激酶活性和EGFR通路。Gefitinib还可以抑制细胞增殖，诱导细胞凋亡，具有抗血管生成活性，在多种肿瘤中具有抗肿瘤活性。

参考文献

[1] Dhar D, et al. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6.

[2] Noh CK, et al.Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. J Sep Sci. 2017 Jul 27.

[3] Morgillo F, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3508-19.

[4] Miyake K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest. 2012;59(1-2):174-85.

冰袋运输。粉末直接保存于-20℃，保持干燥，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。